Project Grant R43AI186674
Award Date 9/5/25
Completion Date 8/31/26
Dollars Obligated $307K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Arkansas, USA
Similar Awards
- This $424,265 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) on August 7, 2025 supports the development of an integrated "DIMS-RAMAN" platform to rapidly isolate and analyze bacterial cells from blood samples within 1-2 hours. The proposed system combines a novel density-shift immunocapture separation (DIMS) technique to directly separate microbial cells from whole blood, with Raman...
- This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award supports the development of a novel device that can rapidly and automatically extract pathogen DNA from whole blood samples to enable faster diagnosis of sepsis. The $274,858 award to New England Hemolytics, Inc., with a project period from September 1, 2024 to February 28, 2025, will fund the testing and optimization of this technology across common sepsis-causing pathogens. The...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded Baebies, Inc., a $1,600,723 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a rapid, point-of-care diagnostic test to identify viable sexually transmitted infections (STIs). The project aims to create a panel of novel STI viability PCR (V-PCR) assays that can differentiate active infection from resolved, non-viable infections. This solution will utilize digital microfluidic...
- This SBIR Phase I Project Grant award of $298,646, provided by the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (CFDA 47.084) program, aims to develop a rapid diagnostic test for identifying sepsis-causing pathogens from small blood volumes. The proposed DNA-based technology seeks to comprehensively detect and quantify a wide range of pathogens within a few hours, addressing limitations of current culture-based methods that require larger blood samples and...
- This federal Project Grant award of $3,055,197.00 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The objective of the project is to evaluate the potential impact of rapid detection of carbapenemase-producing organisms (CPOs) using a form-factor optimized phenotypic test paired with machine learning algorithms. The goal is to increase CPO detection, decrease time-to-identification of CPO...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) totaling $969,449 provides funding to Scanogen Inc., a minority-owned small business, to develop an automated platform for the rapid, comprehensive, and cost-effective identification of yeast in whole blood without the need for blood culture. The platform is powered by an innovative Single Molecule Scanning (SMOLT) technology that demonstrated...
- The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded a $300,000 Project Grant to Electronic Biosciences, Inc. to develop a novel point-of-care technology for monitoring immunosuppressant drug levels. The key product being developed is a portable, fingerstick-based testing system that can provide convenient and frequent immunosuppressant drug level measurements. This will enable more precise dosing for...
- This federal Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), will develop living biosensors to detect and analyze DNA at the single-base level without requiring sample purification or specialized equipment. The $565,614 award will produce a hybrid living biosensor/lateral flow assay that can rapidly detect target DNA sequences,...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $999,316 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Pearl Diagnostics, Inc., a Baltimore-based small business. The grant supports the final integration and clinical testing required for FDA clearance of Pearl Diagnostics' lateral flow device (LFD) - a rapid, point-of-care urine test to diagnose invasive aspergillosis, an infection recently named a "critical" public...
- The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), awarded a $473,937 Project Grant to The General Hospital Corporation (d/b/a Massachusetts General Hospital) for the project "Novel Point-of-Care Liquid Biopsy for Early Detection of Sepsis-Associated Organ Damage". The project aims to develop a novel circulating cellular biomarker for the early detection and assessment of...